Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets [Yahoo! Finance]
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Neurocrine Biosciences' Huntington's disease drug gets FDA approval [Reuters]
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)